0001493152-26-023207
SEC filingNEXGEL reported a 5.6% revenue decline to $2.6M in Q1 FY2026, driven by lower branded consumer product sales despite growth in Medical Device/Other — a transition accompanied by widening operating and net losses, consistent with management’s expectation of near-term losses as the company advances strategic initiatives.
Revenue for Q1 FY2026 was $2.6M, down 5.6% from $2.8M in Q1 FY2025. As disclosed in Item 2, this decrease was primarily due to a decline in branded consumer products, partially offset by an increase in Medical Device/Other revenues — highlighting a deliberate but uneven transition across business segments. Gross profit decreased 10.7% to $1.1M, yet gross margin held steady at 40.0%, consistent with management’s observation that the decrease in cost of revenues aligned with the reduction in sales volume.
Operating income declined 23.3% to -$958.0K, and net income fell 30.2% to -$927.0K. Diluted EPS decreased to -$0.11 from -$0.09. These results reflect the absence of material improvements in scale or efficiency, and are fully consistent with management’s explicit statement: 'We expect to continue incurring losses for the near-term future.' The earnings deterioration occurred without any disclosed change in core revenue drivers beyond the noted segment-level shifts — underscoring that current losses stem from structural portfolio dynamics rather than one-time events.
The company continues to emphasize customer base expansion and proprietary medical device development as foundational to long-term value creation. As stated in Item 2, 'This customer base expansion will enable us to provide financial stability for the foreseeable future, expand our current processes, and position us for long-term shareholder value creation.' Management also notes it 'continues to evaluate strategic initiatives (e.g., acquisitions)' and may pursue debt or equity financing to support those objectives — signaling that capital structure decisions remain responsive to operational milestones rather than near-term profitability.